Search
NLS Pharmaceutics AG
NLSPAdd to Watchlist
0.762USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
20.58MMarket Cap
--P/E TTM
More Details of NLS Pharmaceutics AG Company
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
NLS Pharmaceutics AG Info
Ticker SymbolNLSP
Company nameNewcelX AG
IPO dateJan 29, 2021
CEOZwyer (Alexander)
Number of employees1
Security typeOrdinary Share
Fiscal year-endJan 29
AddressThe Circle 6
CityZUERICH
Stock exchangeNASDAQ Capital Market Consolidated
CountrySwitzerland
Postal code8058
Phone41445122150
Websitehttps://nlspharma.com/
Ticker SymbolNLSP
IPO dateJan 29, 2021
CEOZwyer (Alexander)
Company Executives of NLS Pharmaceutics AG
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
48.53K
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
12.40K
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
3.00K
--
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Ms. Nicole Fernandez-mcgovern
Ms. Nicole Fernandez-mcgovern
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
438.17K
+29.59%
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
48.53K
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
12.40K
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
3.00K
--
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
FAQs
Who are the top five shareholders of NLS Pharmaceutics AG?
The top five shareholders of NLS Pharmaceutics AG are: Mr. Ronald Hafner
How many institutions hold shares of NLS Pharmaceutics AG (NLSP)?
As of 2026Q1, 14 institutions hold shares of NLS Pharmaceutics AG, with a combined market value of approximately 60.72K, accounting for 1.14% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -124181.00.